Semaglutide

Long-acting GLP-1 receptor agonist

Technical datasheetLZH-001

Code: GLP-1 RA
Formula: C187H291N45O59
Molecular weight: 4113.6 Da
Half-life: ~165 h (≈ 7 days)
Research route: Subcutaneous (research)
Molecular targets: GLP-1R (Gs-coupled)
Discovery / disclosure: Disclosed 2012, Novo Nordisk
Target purity: ≥ 98%
Recommended storage: −20°C, light protected. 2 to 8°C after reconstitution.

Aliases

NN9535, Ozempic, Wegovy, Rybelsus

Appearance

White to off-white lyophilized powder

Solubility

Soluble in pH 7.4 aqueous buffer; sparingly soluble in cold water

Sequence

HAibEGTFTSDVSSYLEGQAAK(γE-2xOEG-C18 diacid)EFIAWLVRGRG

Analysts reviewing the HPLC chromatogram for the current batch — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Technician monitoring a stainless steel reactor during scale-up — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Overview

Semaglutide is a long-acting GLP-1 receptor agonist built from a 31 amino acid modified peptide sequence designed for once-weekly dosing. Its structure derives from native GLP-1, with a fatty acid side chain attached at Lys26 to extend half-life.

Pharmacology and mechanism

Activates the GLP-1 receptor, promoting glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying and acting on hypothalamic appetite centers. The effect is glucose-dependent, so hypoglycemia risk is low.

Research areas

R.01

Long-acting GLP-1 receptor agonist

Widely studied in type 2 diabetes metabolic control, obesity management and cardiovascular risk reduction. Active research directions include neurodegenerative disease, NAFLD and addictive behavior modulation.